Literature DB >> 20445618

Hepatitis C: An unsuspected drug target.

Catherine L Murray, Charles M Rice.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20445618     DOI: 10.1038/465042a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  11 in total

Review 1.  Challenges and successes in developing new therapies for hepatitis C.

Authors:  Raffaele De Francesco; Giovanni Migliaccio
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

2.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

3.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

4.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

5.  Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase.

Authors:  Timothy L Tellinghuisen; Joseph Marcotrigiano; Charles M Rice
Journal:  Nature       Date:  2005-05-19       Impact factor: 49.962

6.  Regulation of hepatitis C virion production via phosphorylation of the NS5A protein.

Authors:  Timothy L Tellinghuisen; Katie L Foss; Jason Treadaway
Journal:  PLoS Pathog       Date:  2008-03-21       Impact factor: 6.823

7.  Identification of hepatitis C virus NS5A inhibitors.

Authors:  Julie A Lemm; Donald O'Boyle; Mengping Liu; Peter T Nower; Richard Colonno; Milind S Deshpande; Lawrence B Snyder; Scott W Martin; Denis R St Laurent; Michael H Serrano-Wu; Jeffrey L Romine; Nicholas A Meanwell; Min Gao
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

Review 8.  Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors.

Authors:  Ann D Kwong; Lindsay McNair; Ira Jacobson; Shelley George
Journal:  Curr Opin Pharmacol       Date:  2008-10-17       Impact factor: 5.547

9.  Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly.

Authors:  Nicole Appel; Margarita Zayas; Sven Miller; Jacomine Krijnse-Locker; Torsten Schaller; Peter Friebe; Stephanie Kallis; Ulrike Engel; Ralf Bartenschlager
Journal:  PLoS Pathog       Date:  2008-03-28       Impact factor: 6.823

10.  Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Authors:  Min Gao; Richard E Nettles; Makonen Belema; Lawrence B Snyder; Van N Nguyen; Robert A Fridell; Michael H Serrano-Wu; David R Langley; Jin-Hua Sun; Donald R O'Boyle; Julie A Lemm; Chunfu Wang; Jay O Knipe; Caly Chien; Richard J Colonno; Dennis M Grasela; Nicholas A Meanwell; Lawrence G Hamann
Journal:  Nature       Date:  2010-04-21       Impact factor: 49.962

View more
  3 in total

1.  Significance of endangered and threatened plant natural products in the control of human disease.

Authors:  Mohamed Ali Ibrahim; MinKyun Na; Joonseok Oh; Raymond F Schinazi; Tami R McBrayer; Tony Whitaker; Robert J Doerksen; David J Newman; Louis G Zachos; Mark T Hamann
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-30       Impact factor: 11.205

2.  Hepatitis C: move over interferon.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

3.  TRIM14 inhibits hepatitis C virus infection by SPRY domain-dependent targeted degradation of the viral NS5A protein.

Authors:  Shanshan Wang; Yongzhi Chen; Chunfeng Li; Yaoxing Wu; Lei Guo; Changwei Peng; Yueping Huang; Genhong Cheng; F Xiao-Feng Qin
Journal:  Sci Rep       Date:  2016-08-31       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.